FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589332501> ?p ?o ?g. }

• W2589332501 endingPage "5561" @default.
• W2589332501 startingPage "5561" @default.
• W2589332501 abstract "5561 Background: Concurrent inhibition of EGFR and COX-2 has previously been shown to be an active and well tolerated regimen in recurrent head and neck cancer (Wirth, JCO 23: 6976, 2005). Based on robust preclinical data, we tested concurrent erlotinib and celecoxib as radiosensitizing agents. Methods: Patients with unresectable or high risk adjuvant (microscopic positive margins or extracapsular extension) head and neck cancer and M0 requiring reirradiation were eligible. Eligible patients received celecoxib (200 to 600 mg BID) and erlotinib (150 mg QD) starting 14 days prior to and concurrent with reirradiation (IMRT 60 to 72.4 Gy in 2.2 Gy QD M-F). The primary objective was to determine the safety, tolerability, and maximum tolerated (MTD) dose of celecoxib. The starting dose was celecoxib 200 mg BID escalated to 400 mg BID and 600 mg BID using a 3+3 design with an expanded cohort at the MTD. Results: Between 3/07 to 12/09, 15 pts were enrolled with a median follow-up of 10 months. Patient characteristics include median age 68 (6 age >75); 11 male; 10 with ECOG PS 2, 9 had unresectable disease, 3 with second primaries, 8 received prior chemotherapy and median prior RT dose was 62 Gy. There were no dose limiting toxicities (DLTs) in dose levels (DL) 1 and 2. Two of three patiens at DL3 developed DLTs consisting of gr 3 bone necrosis and trismus. Therefore, celecoxib 400 mg BID was declared the MTD with concurrent erlotinib and reirradiation. Overall gr ≥3 toxicities were uncommon and consisted of gr 3 mucositis (n=3), gr 3 dermatitis (n=2), and gr 3 pain (n=3). At last follow-up, five are alive with no evidence of disease (NED), three developed locoregional progression, three had distant progression, one had both local and distant progression and three are NED but succumbed to comorbid illness. Maintenance erlotinib 150 mg QD until progression was allowed but only 3 patients participated. Conclusions: Concurrent erlotinib, celecoxib and reirradiation is a well tolerated regimen that demonstrates activity in a difficult to treat population of previously irradiated patients. These data suggest that this regimen warrants further study particularly in patients who failed chemoradiation or elderly patients with PS 2. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Pfizer Genentech, sanofi-aventis OSI, Pfizer" @default.
• W2589332501 created "2017-03-03" @default.
• W2589332501 creator A5005580223 @default.
• W2589332501 creator A5012441250 @default.
• W2589332501 creator A5015673570 @default.
• W2589332501 creator A5017952275 @default.
• W2589332501 creator A5031579018 @default.
• W2589332501 creator A5063745166 @default.
• W2589332501 date "2010-05-20" @default.
• W2589332501 modified "2023-10-14" @default.
• W2589332501 title "Phase I trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer." @default.
• W2589332501 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.5561" @default.
• W2589332501 hasPublicationYear "2010" @default.
• W2589332501 type Work @default.
• W2589332501 sameAs 2589332501 @default.
• W2589332501 citedByCount "1" @default.
• W2589332501 countsByYear W25893325012016 @default.
• W2589332501 crossrefType "journal-article" @default.
• W2589332501 hasAuthorship W2589332501A5005580223 @default.
• W2589332501 hasAuthorship W2589332501A5012441250 @default.
• W2589332501 hasAuthorship W2589332501A5015673570 @default.
• W2589332501 hasAuthorship W2589332501A5017952275 @default.
• W2589332501 hasAuthorship W2589332501A5031579018 @default.
• W2589332501 hasAuthorship W2589332501A5063745166 @default.
• W2589332501 hasConcept C121608353 @default.
• W2589332501 hasConcept C126322002 @default.
• W2589332501 hasConcept C141071460 @default.
• W2589332501 hasConcept C143998085 @default.
• W2589332501 hasConcept C197934379 @default.
• W2589332501 hasConcept C2776467144 @default.
• W2589332501 hasConcept C2776530083 @default.
• W2589332501 hasConcept C2778087573 @default.
• W2589332501 hasConcept C2778375690 @default.
• W2589332501 hasConcept C2779438470 @default.
• W2589332501 hasConcept C2781413609 @default.
• W2589332501 hasConcept C71924100 @default.
• W2589332501 hasConceptScore W2589332501C121608353 @default.
• W2589332501 hasConceptScore W2589332501C126322002 @default.
• W2589332501 hasConceptScore W2589332501C141071460 @default.
• W2589332501 hasConceptScore W2589332501C143998085 @default.
• W2589332501 hasConceptScore W2589332501C197934379 @default.
• W2589332501 hasConceptScore W2589332501C2776467144 @default.
• W2589332501 hasConceptScore W2589332501C2776530083 @default.
• W2589332501 hasConceptScore W2589332501C2778087573 @default.
• W2589332501 hasConceptScore W2589332501C2778375690 @default.
• W2589332501 hasConceptScore W2589332501C2779438470 @default.
• W2589332501 hasConceptScore W2589332501C2781413609 @default.
• W2589332501 hasConceptScore W2589332501C71924100 @default.
• W2589332501 hasIssue "15_suppl" @default.
• W2589332501 hasLocation W25893325011 @default.
• W2589332501 hasOpenAccess W2589332501 @default.
• W2589332501 hasPrimaryLocation W25893325011 @default.
• W2589332501 hasRelatedWork W1562823317 @default.
• W2589332501 hasRelatedWork W1968036257 @default.
• W2589332501 hasRelatedWork W2007986200 @default.
• W2589332501 hasRelatedWork W2009822178 @default.
• W2589332501 hasRelatedWork W2137859389 @default.
• W2589332501 hasRelatedWork W2171389860 @default.
• W2589332501 hasRelatedWork W2281121233 @default.
• W2589332501 hasRelatedWork W2354297587 @default.
• W2589332501 hasRelatedWork W2890017731 @default.
• W2589332501 hasRelatedWork W3124087888 @default.
• W2589332501 hasVolume "28" @default.
• W2589332501 isParatext "false" @default.
• W2589332501 isRetracted "false" @default.
• W2589332501 magId "2589332501" @default.
• W2589332501 workType "article" @default.